PRIMA BIOMED LIMITED
AND ITS CONTROLLED ENTITIES
ABN 90 009 237 889

APPENDIX 4D
HALF YEARLY FINANCIAL REPORT

for the half year ending
31 December 2003

Half-year information given to ASX under listing rule 4.2A

This document should be read in conjunction with the 30 June 2003 Annual Report.

RESULTS FOR ANNOUNCEMENT TO THE MARKET

Revenues from ordinary activities	up	41.26%	to	$122,067
Loss from ordinary activities after tax attributable to members	up	5.44%	to	($2,192,698)
Net loss for the period attributable to members	up	5.44%	to	($2,192,698)

Dividends (distributions)	Amount per security	Franked amount per security
Final dividend	n/a	n/a
Previous corresponding period	n/a	n/a

[+]Record date for determining entitlements to the dividend, (in the case of a trust, distribution)	n/a

Explanation of the above information:

DIRECTORS' REPORT

Your directors submit the financial report of the economic entity for the half-year ended 31 December 2003.

Directors

The names of directors who held office during or since the end of the half-year:

Bryan Frost	Executive Chairman
Marcus Clark	Executive Director and CEO
Richard Revelins	Finance Director
Mark Hogarth	Non-Executive Director
Kevin Fahey	Non-Executive Director (resigned 23 January 2004)

Review of Operations

During the period the company's primary focus has been planning and preparation for its Phase II clinical trial for Cancer Vac, completing predetermined scientific milestones for Oncomab and Panvax and continuing negotiations with potential licencing partners in respect of the company's major areas of interest. These negotiations which have been ongoing for some time gathered considerable momentum during December 2003 and the company is hoping to be in a position to disclose details in relation to some of these matters shortly.

Arthron

Arthron achieved its established scientific end points during the 2003 financial year. Since then Prima management working together with the Austin Research Institute have included the research data into a full technical dossier which has been made available to select pharmaceutical companies for the purposes of evaluation. A number of these companies have expressed strong commercial interest in the technology and negotiations have been ongoing for some time.

The aim of current negotiations is a licensing deal for Arthron whereby a major pharmaceutical company would agree to fund the ongoing development of Arthron's Fc Receptor related therapy and then through clinical development and product distribution. Arthron is negotiating upfront fees and milestone payments on an ongoing basis as milestones are achieved and royalty income from the future sales of therapeutics.

Cancer Vac

Following from the success of Cancer Vac's Phase 1 and Phase 1b trials the company in partnership with the Austin Research Institute resolved to embark on a Phase II clinical trial in ovarian cancer. It was previously announced in October last year that agreement had been reached with Progen Limited for Progen to manufacture Cancer Vac's drug to GMP standards for use in the trial. The trial protocol will be submitted this month (February) to the Austin Health Ethics Committee and upon approval will allow patient screening to commence during April/May.

The women who participate in the trial will have only received first-line chemotherapy and therefore will still have relatively strong immune systems. Accordingly it is anticipated that these patients should respond well to Cancer Vac's immunotherapy.

The trial has also received strong support from the doctors at four of the key teaching hospitals involved in the treatment of ovarian cancer, the Royal Womens Hospital, the Mercy Hospital, Austin Health and the Monash Medical Centre. The co-operation between these leading medical centres in the trial represents a strong endorsement of Cancer Vac's scientific approach.

Oncomab

The program with leading US based monoclonal antibody company Medarex Inc commenced in March 2003. The agreement has been established to produce a suite of human therapeutic antibodies which bind to proteins found on the surface of cancer cells. Interaction of the surface proteins with the antibody leads to cell death. The proteins are found on a number of solid tumours including those of the breast, lung, colon, ovary and prostrate gland, but is not found on healthy cells. Research undertaken in animal models undertaken to date by Oncomab and the Austin Research Institute provides evidence that responses to Oncomab's monoclonal antibody therapy exceed those previously reported by existing therapies currently in commercial use. The Medarex agreement is designed to humanise the antibodies discovered by Oncomab and develop these into effective cancer therapies.

Panvax

In August 2003 Panvax announced its critical finding that Panvax's proprietory DCtag technology can be chemically linked to proteins associated with both human cancers and also viral proteins converting them to potent stimulators of immune responses. Research also indicates that DCtag can probably be linked to most protein-based vaccines to make them more effective at preventing or treating disease.

DCtag has passed its first toxicology testing program in animals, indicating that it is likely to be safe for injection into humans. Panvax is progressing this technology towards a therapeutic product for stimulating immune responses.

During August 2003 Panvax announced that it had entered into a collaboration agreement with Prana Biotechnology Ltd to use Panvax's DCtag technology as the basis for creating a potential vaccine for Alzheimers Disease. Prana is regarded as a leading company in the field of Alzheimers Disease therapy after successfully demonstrating proof of concept in its Phase II clinical trial.

Panvax will be taking results in cancer into a pre clinical program and Phase 1 study with DCtag linked to a cancer antigen. In addition the platform development will continue through a number of collaborations, an outline of which is described below.

Collaborator	Disease	Status	About the disease
Institute Pasteur, France	Malaria	Awaiting results from mouse immunisation trials	Malaria infects almost 0.5 billion people annually, causing 1 to 3 million deaths
Malaria Vaccine Initiative, US	Malaria	Awaiting final DC tag characterisation	
Prana Biotechnology, Melbourne	Alzheimer's disease	Immunisation to protect against 'Alzheimer's-like' Disease in mice has commenced	Alzheimer's affects about 12% of people over age 65 and 50% of those over 85 in developing countries
Centre of Animal Biotechnology, Melbourne	Foot and Mouth virus in cattle	Development program to commence in April 2004	FMV is one of the most serious threats to world agriculture. It affects cows, sheep and pigs

Capital Raising Activities

On 8 August 2003, the company announced that it had reached an agreement for the private placement of up to 7.36 million new ordinary shares to institutional and sophisticated investors at an issue price of 37 cents per share. The placement raised approximately $2.72 million before allowing for costs associated with the issue.

On 21 August 2003, the company announced to the market that it had reached agreement for a further private placement of up to 11.62 million new ordinary shares to institutional and sophisticated investors at an issue price of 37 cents per share, subject to shareholder

approval. Shareholder approval was received at the General Meeting held on 26 September 2003. The placement raised approximately $3.5 million before allowing for associated costs.

As a result of these announcements, 16.8 million shares were issued, raising $6.2 million less capital raising costs. The funds are being applied towards the company's scientific development program and working capital purpos es.

Directors Options

In the half-year ending 31 December 2003, no options were issued to directors of the company as part of their emolument.

This report is signed in accordance with a resolution of the Board of Directors.

Bryan Frost
Executive Chairman

Dated this 27th day of February 2004

CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2003

	ECONOMIC ENTITY	
	31 December 2003	30 June 2003
	$	$
CURRENT ASSETS		
Cash assets	**4,823,925**	1,578,519
Receivables	**177,934**	66,499
Other	**50,780**	-
TOTAL CURRENT ASSETS	**5,052,639**	1,645,018
NON-CURRENT ASSETS		
Plant and equipment	**65,625**	67,095
Intangibles	**2,195,120**	2,256,218
TOTAL NON-CURRENT ASSETS	**2,260,745**	2,323,313
TOTAL ASSETS	**7,313,384**	3,968,331
CURRENT LIABILITIES		
Payables	**367,206**	854,726
Provisions	**15,744**	18,196
TOTAL CURRENT LIABILITIES	**382,950**	872,922
NON-CURRENT LIABILITIES		
Provisions	**1,961**	1,961
TOTAL NON-CURRENT LIABILITIES	**1,961**	1,961
TOTAL LIABILITIES	**384,911**	874,883
NET ASSETS	**6,928,473**	3,093,448
EQUITY		
Contributed equity	**24,431,246**	18,403,523
Accumulated losses	**(17,502,773)**	(15,310,075)
Total parent entity interest in equity	**6,928,473**	3,093,448
Total Outside Equity Interest	**-**	-
TOTAL EQUITY	**6,928,473**	3,093,448

The accompanying notes form part of these financial statements.

CONSOLIDATED STATEMENT OF FINANCIAL PERFORMANCE FOR THE HALF YEAR ENDED 31 DECEMBER 2003

	ECONOMIC ENTITY	
	31 December 2003 $	31 December 2002 $
REVENUES FROM ORDINARY ACTIVITIES	**122,067**	86,411
Business Development	**(699,149)**	(1,071,750)
Product Development	**(141,365)**	(160,192)
Intellectual Property	**(178,621)**	(53,430)
Research and Development	**(1,224,335)**	(1,489,161)
Amortisation of Intangibles	**(61,099)**	(53,024)
Depreciation	**(10,196)**	(4,306)
(LOSS) FROM ORDINARY ACTIVITIES BEFORE INCOME TAX EXPENSE	**(2,192,698)**	(2,745,452)
INCOME TAX EXPENSE RELATING TO ORDINARY ACTIVITIES	-	-
(LOSS) FROM ORDINARY ACTIVITIES AFTER INCOME TAX EXPENSE	**(2,192,698)**	(2,745,452)
NET (LOSS) ATTRIBUTABLE TO OUTSIDE EQUITY INTEREST	-	665,915
NET (LOSS) ATTRIBUTABLE TO MEMBERS OF THE PARENT ENTITY	**(2,192,698)**	(2,079,537)
TOTAL CHANGES IN EQUITY OTHER THAN THOSE RESULTING FROM TRANSACTIONS WITH OWNERS AS OWNERS	**(2,192,698)**	(2,079,537)
BASIC EARNINGS PER SHARE (cents per share)	(3.57)	(5.03)
DILUTED EARNINGS PER SHARE (cents per share)	(3.57)	(5.03)

The accompanying notes form part of these financial statements.

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED 31 DECEMBER 2003

	ECONOMIC ENTITY	
	31 December 2003 $	31 December 2002 $
CASH FLOWS FROM OPERATING ACTIVITIES		
Receipts	**16,217**	80,906
Payments to suppliers and employees	**(2,781,610)**	(2,911,021)
Interest received	**60,040**	3,710
Other	**3,761**	-
NET CASH FLOWS FROM/(USED IN) OPERATING ACTIVITIES	**(2,701,592)**	(2,826,405)
CASH FLOWS FROM INVESTING ACTIVITIES		
Payment for purchases of property, plant and equipment	**(8,725)**	(339,254)
NET CASH FLOWS FROM/(USED IN) INVESTING ACTIVITIES	**(8,725)**	(339,254)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from issue of shares & other equity securities	**6,418,553**	3,351,827
Capital Raising Costs	**(462,830)**	(195,807)
NET CASH FLOWS FROM/(USED IN) FINANCING ACTIVITIES	**5,955,723**	3,156,020
NET INCREASE/(DECREASE) IN CASH HELD	**3,245,406**	(9,639)
Opening Cash Balance at 1 July	**1,578,519**	3,714,557
Closing Cash Balance at 31 December	**4,823,925**	3,704,918

The accompanying notes form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF YEAR ENDED 31 DECEMBER 2003

Note 1. Basis of Preparation

The half-year consolidated financial statements are a general purpose financial report prepared in accordance with the requirements of the Corporations Act 2001, Accounting Standards AASB 1029: Interim Financial Reporting, Urgent Issues Group Consensus Views and other authoritative pronouncements of the Australian Accounting Standards Board.

It is recommended that this financial report be read in conjunction with the annual financial report for the year ended 30 June 2003 and any public announcements made by Prima Biomed Limited and its controlled entities during the half-year in accordance with continuous disclosure requirements arising under the Corporations Act 2001.

The accounting policies have been consistently applied by the entities in the economic entity and are consistent with those applied in the 30 June 2003 annual report.

The half-year report does not include full disclosures of the type normally included in the annual financial report.

Note 2. Segment Information

Primary Reportable Segment - Business

	Cancer Immunotherapy	Rehumatoid Arthritis	Drug Delivery Systems	Therapeutic Antibodies for Cancer	Eliminations	Economic Entity
	$	$	$	$	$	$
Segment Revenue						
External	426	412	54,545	31	-	55,414
Inter-Segment Sales						-
Total Segment Revenue	426	412	54,545	31	-	55,414
Unallocated Revenue						66,653
Consolidated Revenue						122,067
Segment Result	(581,940)	(209,460)	(456,624)	(275,002)	241,286	(1,281,740)
Add Unallocated Revenue						66,653
Less Unallocated Expenses						(977,611)
Profit from Ordinary Activities before Income Tax						(2,192,698)
Income Tax Expense						-
Profit from Ordinary Activities after Income Tax						(2,192,698)
Segment Assets	(1,135,655)	(1,275,789)	904,256	144,987	-	(1,362,201)
Unallocated Assets						8,675,585
Consolidated Total Assets						7,313,384
Segment Liabilities	143,451	127,481	13,381	12,545	(44,146)	252,712
Unallocated Liabilities						132,199
Consolidated Total Liabilities						384,911

Secondary Reportable Segment - Geographical

Prima Biomed Limited operates in one geographical segment, being Australia.

Note 3. Contingent Liabilities

There has been no change in contingent liabilities since the last annual reporting date.

Note 4. Events Subsequent to Reporting Date

There have been no events after reporting date that have a material effect on this report.

Note 5. Net Tangible Asset Backing

	31 December 2003	30 June 2003
Net Assets	$6,928,473	$3,093,448
Intangible Assets	$2,195,120	$2,256,218
Net Tangible Assets	$4,733,353	$837,230
Number of Shares on Issue	68,613,483	50,501,840
Net Tangible Asset Backing (cents)	6.90	1.66

DIRECTORS' DECLARATION

The directors of the company declare that:

1. The financial statements and notes, as set out in pages 6 to 11:

   a. Comply with Accounting Standard AASB 1029: Interim Financial Reporting and the Corporations Regulations; and

   b. Give a true and fair view of the economic entity's financial position as at 31 December 2003 and of its performance for the half-year ended on that date.

2. In the directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.

Director
Bryan Frost

Dated this 27th day of February 2004

Hall Chadwick
Chartered Accountants & Business Advisers

Melbourne
Level 9
459 Collins Street
Melbourne 3000
Victoria Australia

DX 505 Melbourne

Telephone: (03) 8625 5200
Facsimile: (03) 9614 5495
Email: hcmelinfo@hall chadwick.com.au

Melton
297 High Street
Melton 3337
Victoria Australia

Telephone: (03) 9743 1333
Facsimile: (03) 9614 5495
Email: hcmelinfo@hall chadwick.com.au

INDEPENDENT REVIEW REPORT
TO THE MEMBERS OF PRIMA BIOMED LIMITED

Scope

We have reviewed the financial report of Prima BioMed Limited for the half-year ended 31 December 2003 as set out on pages 6 to 12. The financial report includes the consolidated financial statements of the consolidated entity comprising the company and the entities it controlled at the end of the half-year or from time to time during the half-year. The company's directors are responsible for the financial report. We have performed an independent review of the financial report in order to state whether, on the basis of the procedures described, anything has come to our attention that would indicate that the financial report is not presented fairly in accordance with Accounting Standard AASB 1029 "Interim Financial Reporting" and other mandatory financial reporting requirements in Australia and statutory requirements, so as to present a view which is consistent with our understanding of the company's financial position, and performance as represented by the results of its operations and its cash flows, and in order for the company to lodge the financial report with the Australian Securities and Investments Commission and the Australian Stock Exchange Limited.

Our review has been conducted in accordance with Australian Auditing and Assurance Standards applicable to review engagements. A review is limited primarily to inquiries of the company's personnel and analytical procedures applied to the financial data. These procedures do not provide all the evidence that would be required in an audit, thus the level of assurance is less than given in an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Statement

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Prima Biomed Limited is not in accordance with:

(a) the Corporations Act 2001, including:
  (i) giving a true and fair view of the company's financial position as at 31 December 2003 and of its performance for the half-year ended on that date; and
  (ii) complying with Accounting Standard AASB 1029 "Interim Financial Reporting" and the Corporations Regulations 2001; and

(b) other mandatory financial reporting requirements in Australia.

Hall Chadwick

HALL CHADWICK
Chartered Accountants

Robert L Yeo

ROBERT L YEO
Partner

Melbourne
27 February, 2004